CapsoVision, Inc. CV R2K
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 17.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -62.0% CAGR over 5 years.
- Trading 53.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CV CapsoVision, Inc. R2K | 6.78 | - | $338.75M | - | - | - | 17.89% | -61.96% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.84M | - | 2.78M | 3.31M | 3.54M | 3.92M | 2.79M |
| Cost of Revenue | - | - | - | 1.29M | 1.50M | 1.62M | 1.96M | 1.46M |
| Gross Profit | - | 1.59M | - | 1.49M | 1.81M | 1.91M | 1.95M | 1.33M |
| Operating Expenses | - | - | - | 6.88M | 6.46M | 9.93M | 9.42M | 8.42M |
| Operating Income | - | -5.27M | - | -5.38M | -4.65M | -8.02M | -7.46M | -7.09M |
| EBITDA | - | - | - | -5.25M | -4.51M | -7.88M | -7.32M | -6.94M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -5.38M | -4.62M | -7.92M | -7.37M | -7.03M |
| Tax Provision | - | - | - | 0 | 0 | 0 | 24.00K | 0 |
| Net Income | -4.20M | -5.27M | - | -5.38M | -4.62M | -7.92M | -7.39M | -7.03M |
| Diluted EPS | - | -2.58 | -0.14 | -0.12 | -0.10 | -0.17 | - | -0.15 |
| R&D Expense | - | 4.22M | 4.52M | 3.11M | 3.39M | 6.09M | - | 4.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 9.75M | 11.76M | 13.55M |
| Cost of Revenue | 4.26M | 5.38M | 6.38M |
| Gross Profit | 5.49M | 6.38M | 7.17M |
| Operating Expenses | 16.84M | 26.29M | 32.69M |
| Operating Income | -11.35M | -19.92M | -25.52M |
| EBITDA | -10.96M | -19.40M | -24.95M |
| Interest Expense | - | - | - |
| Pretax Income | -11.29M | -19.89M | -25.29M |
| Tax Provision | 11.00K | 11.00K | 24.00K |
| Net Income | -11.30M | -19.90M | -25.32M |
| Diluted EPS | -0.29 | -0.43 | -1.03 |
| R&D Expense | - | 15.12M | 18.31M |
Compounded Sales Growth
| 5 Years: | 17.89% |
| 1 Year: | 0.30% |
Compounded Profit Growth
| 5 Years: | -61.96% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +93.71% |
| 6 Months: | +23.27% |
| 3 Months: | +23.50% |
| 1 Month: | +5.94% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 21.53M | 16.80M | 18.16M |
| Current Assets | 19.20M | 14.85M | 16.67M |
| Cash & Equivalents | 14.56M | 9.32M | 10.11M |
| Inventory | 2.19M | 2.63M | 2.99M |
| Receivables | 1.87M | 2.00M | 2.50M |
| Total Liabilities | 131.37M | 146.31M | 4.90M |
| Current Liabilities | 1.51M | 1.80M | 4.43M |
| Long Term Debt | - | - | - |
| Total Debt | 1.51M | 1.24M | 887.00K |
| Total Equity | -109.84M | -129.51M | 13.26M |
| Shares Outstanding | 46.34M | 46.34M | 46.87M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -10.80M | -20.09M | -22.86M |
| Investing Cash Flow | -754.00K | -153.00K | -90.00K |
| Financing Cash Flow | 20.53M | 15.07M | 23.60M |
| Capital Expenditure | -754.00K | -153.00K | -90.00K |
| Free Cash Flow | -11.56M | -20.24M | -22.95M |
| Net Change in Cash | 8.97M | -5.17M | 650.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 56.3% | 54.2% | 52.9% |
| Operating Margin % | -116.3% | -169.4% | -188.3% |
| Net Margin % | -115.9% | -169.3% | -186.8% |
| ROE % | 10.3% | 15.4% | -190.9% |
| ROCE % | -56.7% | -132.8% | -185.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 2.61% | 1.30M | $8.84M |
| 2 | Vanguard Capital Management LLC | 2.05% | 1.03M | $6.96M |
| 3 | Geode Capital Management, LLC | 0.87% | 435.15K | $2.95M |
| 4 | State Street Corporation | 0.51% | 256.04K | $1.74M |
| 5 | Vanguard Portfolio Management LLC | 0.33% | 164.39K | $1.11M |
| 6 | Northern Trust Corporation | 0.30% | 152.33K | $1.03M |
| 7 | Vanguard Fiduciary Trust Co | 0.18% | 88.63K | $600.92K |
| 8 | UBS Group AG | 0.13% | 65.16K | $441.76K |
| 9 | Xtx Topco Ltd | 0.13% | 67.38K | $456.84K |
| 10 | Charles Schwab Investment Management, Inc. | 0.12% | 61.38K | $416.14K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CV